Drug Profile
Levofloxacin inhalation - Horizon Therapeutics plc
Alternative Names: Aeroquin; Inhaled levofloxacin hemihydrate - Horizon Therapeutics plc; MP 376; QuinsairLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator Mpex Pharmaceuticals
- Developer Adare Pharmaceuticals; Horizon Therapeutics plc
- Class Anti-infectives; Antibacterials; Fluoroquinolones; Small molecules
- Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Cystic fibrosis-associated respiratory tract infections
- Discontinued Bronchiectasis; Nontuberculous mycobacterium infections; Respiratory tract infections
Most Recent Events
- 28 Dec 2022 Discontinued - Preclinical for Bronchiectasis (Non-cystic fibrosis-related) in USA (Inhalation)
- 28 Dec 2022 Discontinued - Preclinical for Nontuberculous mycobacterium infections in USA (Inhalation)
- 05 Sep 2021 Interim pharmacodynamics data from a preclinical trial in cystic fibrosis presented at the 31st Annual Congress of the European Respiratory Society (ERS-2021)